Human Urinary kallidinogenase promotes good recovery in ischemic stroke patients with level 3 hypertension.

Danhong Wu,Yi Lyu,Ping Zhong,Xueyuan Liu,Fengdi Liu

doi:10.1002/brb3.752

Abstract

AimTo evaluate the clinical efficacy of Human Urinary kallidinogenase (HUK) in the treatment of acute ischemic stroke (AIS) patients with level 3 hypertension.MethodsIn this retrospective study, from January 2015 to June 2016, 150 consecutive AIS patients were registered in our database. Among them, 47 with level 3 hypertension received either HUK treatment (HUK group, 22 cases) or basic treatment (control group, 25 cases). Basic treatment was administrated on all patients. 0.15 PNA unit of HUK injection plus 100 ml saline in intravenous infusion was performed in the HUK group, with once a day for 14 consecutive days. The modified Rankin Scale (mRS) scores in two groups were analyzed 3 months after the treatment.ResultsNo difference was found in the NIHSS scores, age, gender, and comorbidities between two groups before treatment (p > .05). While after treatment, 3‐month mRS score was significantly lower in the HUK group (2.1 ± 1.4 vs. 3.1 ± 1.3, p = .012) and good recovery rate (3‐month mRS score ≤2) in the HUK group was significantly higher than that in the control group (p < .05).Conclusion HUK is able to promote long‐term recovery for AIS patients with level 3 hypertension remarkably.

Highlights

Stroke is the leading cause of death and disability in China (Bazzano et al, 2007) and the second most common cause of death worldwide after coronary heart disease (Reed, 1990)
The kallikrein–kinin system consisting of kinins, kallikreins, and kininogens have been shown to protect against ischemic stroke in patients (Zhang et al, 2012) and animal studies (Chen et al, 2010)
With approved medicine of H20052065) plus100 mL saline in intravenous infusion was taken in the Human Urinary kallidinogenase (HUK) group, with once a day for 14 consecutive days

Summary

Introduction

Stroke is the leading cause of death and disability in China (Bazzano et al, 2007) and the second most common cause of death worldwide after coronary heart disease (Reed, 1990). The epidemiological data show that from 1984 to 2004 the incidence of acute ischemic stroke (AIS) as the most common subtype, representing about 80% of all strokes, has increased by 8.7% per year in China (Jia, Liu, & Wang, 2010). In the past 50 years, several important risk factors for AIS have been identified, including hypertension, diabetes, smoking, and dyslipidemia (Sever et al, 2003; Wong et al, 2001). The kallikrein–kinin system consisting of kinins, kallikreins, and kininogens have been shown to protect against ischemic stroke in patients (Zhang et al, 2012) and animal studies (Chen et al, 2010).

Objectives

Methods

Findings

Conclusion